Point of Care Clinical Risk Score to Improve the Negative Diagnostic Utility of an Agatston Score of Zero: Averting the Need for Coronary Computed Tomography Angiography.
chest pain
coronary artery disease
diabetes mellitus
humans
registries
Journal
Circulation. Cardiovascular imaging
ISSN: 1942-0080
Titre abrégé: Circ Cardiovasc Imaging
Pays: United States
ID NLM: 101479935
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
entrez:
19
9
2019
pubmed:
19
9
2019
medline:
9
6
2020
Statut:
ppublish
Résumé
Coronary artery calcification is a marker of underlying atherosclerotic vascular disease. The absence of coronary artery calcification is associated with a low prevalence of obstructive coronary artery disease (CAD), but it cannot be ruled out completely. We sought to develop a clinical tool that can be added to Agatston score of zero to rule out obstructive CAD with high accuracy. We developed a clinical score retrospectively from a cohort of 4903 consecutive patients with an Agatston score of zero. Patients with prior diagnosis of CAD, coronary percutaneous coronary intervention, or surgical revascularization were excluded. Obstructive CAD was defined as any epicardial vessel diameter narrowing of ≥50%. The score was validated using an external cohort of 4290 patients with an Agatston score of zero from a multinational registry. The score consisted of 7 variables: age, sex, typical chest pain, dyslipidemia, hypertension, family history, and diabetes mellitus. The model was robust with an area under the curve of 0.70 (95% CI, 0.65-0.76) in the derivation cohort and 0.69 (95% CI, 0.65-0.72) in the validation cohort. Patients were divided into 3 risk groups based on the score: low (≤6), intermediate (7-13), and high (≥14). Patients who score ≤6 have a negative likelihood ratio of 0.42 for obstructive CAD, whereas those who score ≥14 have a positive likelihood ratio of >5.5 for obstructive CAD. The outcome was ruled out in >98% of patients with a score ≤6 in the validation cohort. We developed a score that may be used to identify the likelihood of obstructive CAD in patients with an Agatston score of zero, which may be used to direct the need for additional testing. However, the results of this retrospective analysis are hypothesis generating and before clinical implementation should be validated in a trial with a prospectively collected data.
Sections du résumé
BACKGROUND
Coronary artery calcification is a marker of underlying atherosclerotic vascular disease. The absence of coronary artery calcification is associated with a low prevalence of obstructive coronary artery disease (CAD), but it cannot be ruled out completely. We sought to develop a clinical tool that can be added to Agatston score of zero to rule out obstructive CAD with high accuracy.
METHODS
We developed a clinical score retrospectively from a cohort of 4903 consecutive patients with an Agatston score of zero. Patients with prior diagnosis of CAD, coronary percutaneous coronary intervention, or surgical revascularization were excluded. Obstructive CAD was defined as any epicardial vessel diameter narrowing of ≥50%. The score was validated using an external cohort of 4290 patients with an Agatston score of zero from a multinational registry.
RESULTS
The score consisted of 7 variables: age, sex, typical chest pain, dyslipidemia, hypertension, family history, and diabetes mellitus. The model was robust with an area under the curve of 0.70 (95% CI, 0.65-0.76) in the derivation cohort and 0.69 (95% CI, 0.65-0.72) in the validation cohort. Patients were divided into 3 risk groups based on the score: low (≤6), intermediate (7-13), and high (≥14). Patients who score ≤6 have a negative likelihood ratio of 0.42 for obstructive CAD, whereas those who score ≥14 have a positive likelihood ratio of >5.5 for obstructive CAD. The outcome was ruled out in >98% of patients with a score ≤6 in the validation cohort.
CONCLUSIONS
We developed a score that may be used to identify the likelihood of obstructive CAD in patients with an Agatston score of zero, which may be used to direct the need for additional testing. However, the results of this retrospective analysis are hypothesis generating and before clinical implementation should be validated in a trial with a prospectively collected data.
Identifiants
pubmed: 31526300
doi: 10.1161/CIRCIMAGING.118.008737
pmc: PMC7099843
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e008737Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : ErratumIn
Références
Arch Intern Med. 2004 Jun 28;164(12):1285-92
pubmed: 15226161
Am Heart J. 2005 Jun;149(6):1112-9
pubmed: 15976796
Am Heart J. 2001 Mar;141(3):375-82
pubmed: 11231434
Eur Heart J. 2011 Jun;32(11):1316-30
pubmed: 21367834
J Am Coll Cardiol. 2010 Oct 19;56(17):1407-14
pubmed: 20946998
J Am Coll Cardiol. 1990 Mar 15;15(4):827-32
pubmed: 2407762
J Cardiovasc Comput Tomogr. 2011 Mar-Apr;5(2):84-92
pubmed: 21477786
Am J Epidemiol. 2005 Sep 1;162(5):421-9
pubmed: 16076829
J Cardiovasc Comput Tomogr. 2009 Mar-Apr;3(2):122-36
pubmed: 19272853
Circulation. 2016 Mar 1;133(9):849-58
pubmed: 26801055
J Am Coll Cardiol. 2005 Jul 5;46(1):158-65
pubmed: 15992651
Atherosclerosis. 2015 Aug;241(2):495-7
pubmed: 26091973
J Am Coll Cardiol. 2010 Feb 16;55(7):627-34
pubmed: 20170786
Circulation. 2008 Apr 1;117(13):1693-700
pubmed: 18362235
J Am Coll Cardiol. 2011 Dec 6;58(24):2533-40
pubmed: 22079127
N Engl J Med. 2008 Mar 27;358(13):1336-45
pubmed: 18367736
Atherosclerosis. 2009 Apr;203(2):533-7
pubmed: 18774135
J Am Coll Cardiol. 2005 Sep 6;46(5):807-14
pubmed: 16139129
JACC Cardiovasc Imaging. 2009 Jun;2(6):675-88
pubmed: 19520336
Eur Heart J Cardiovasc Imaging. 2014 Mar;15(3):267-74
pubmed: 23966421
Ann Intern Med. 2006 Feb 7;144(3):165-71
pubmed: 16461960
J Am Coll Cardiol. 2010 Mar 9;55(10):1017-28
pubmed: 20202518
JAMA. 2010 Apr 28;303(16):1610-6
pubmed: 20424251
Eur Radiol. 2010 Jan;20(1):81-7
pubmed: 19657651
J Am Coll Cardiol. 2015 Oct 13;66(15):1643-53
pubmed: 26449133
N Engl J Med. 1979 Jun 14;300(24):1350-8
pubmed: 440357
Stat Med. 1984 Apr-Jun;3(2):143-52
pubmed: 6463451
J Cardiovasc Comput Tomogr. 2014 Sep-Oct;8(5):342-58
pubmed: 25301040
Eur Heart J Cardiovasc Imaging. 2017 May 1;18(8):922-929
pubmed: 28379388
JACC Cardiovasc Imaging. 2010 Dec;3(12):1229-36
pubmed: 21163451
Am J Cardiol. 2007 Feb 15;99(4):472-5
pubmed: 17293187
J Am Coll Cardiol. 2010 Oct 19;56(17):1397-406
pubmed: 20946997
Stat Med. 2004 May 30;23(10):1631-60
pubmed: 15122742